Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bailing Capsule for Pulmonary Fibrosis After COVID-19
NCT05890573Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- TCM (Traditional Chinese Medicine), Biologic
- Countries
- 1
01
Overview
Randomised, open-label trial of bailing capsule in pulmonary fibrosis (PF) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Rate of clinically significant change in FVC and/or DLCO at 12 weeks. Status: unknown.
02
Drugs
bailing capsule
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT05890573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890573.